학술논문
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer
Document Type
Article
Author
Holloway, R.W.; Ahmad, S.; Thaker, P.; Mendivil, A.A.; Beck, T.; Al-Niaimi, A.N.; Barter, J.; Chambers, S.K.; Coleman, R.L.; Crafton, S.M.; Crane, E.; Ramez, E.; Ghamande, S.; Graybill, W.; Herzog, T.; Indermaur, M.D.; John, V.S.; Landrum, L.; Lim, P.C.; Lucci, J.A.; Mchale, M.; Monk, B.J.; Moore, K.N.; Morris, R.; O'malley, D.M.; Reid, T.J.; Richardson, D.; Rose, P.G.; Scalici, J.M.; Silasi, D.-A.; Tewari, K.; Wang, E.W.
Source
In: International Journal of Gynecological Cancer . (International Journal of Gynecological Cancer, 1 September 2023, 33(9):1458-1463)
Subject
Language
English
ISSN
15251438
1048891X
1048891X